Does the media refer more to PHAT or SGMT?

In the previous week, Phathom Pharmaceuticals had 17 more articles in the media than Sagimet Biosciences. MarketBeat recorded 20 mentions for Phathom Pharmaceuticals and 3 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.17 beat Phathom Pharmaceuticals' score of 0.01 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PHAR or SGMT?

In the previous week, Pharming Group had 22 more articles in the media than Sagimet Biosciences. MarketBeat recorded 25 mentions for Pharming Group and 3 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.17 beat Pharming Group's score of -0.11 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 2 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SGMT or JANX more profitable?

Janux Therapeutics' return on equity of -12.93% beat Sagimet Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -37.57% -35.52% Janux Therapeutics N/A -12.93% -12.23%

Does the media favor SGMT or JANX?

In the previous week, Sagimet Biosciences had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 3 mentions for Sagimet Biosciences and 2 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.44 beat Sagimet Biosciences' score of 0.17 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SGMT or AMPH?

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Sagimet Biosciences. MarketBeat recorded 4 mentions for Amphastar Pharmaceuticals and 3 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.17 beat Amphastar Pharmaceuticals' score of 0.12 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PURR or SGMT more profitable?

Sagimet Biosciences' return on equity of -37.57% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Hyperliquid Strategies N/A -56.04% -52.22% Sagimet Biosciences N/A -37.57% -35.52%

Does the media refer more to PURR or SGMT?

In the previous week, Hyperliquid Strategies and Hyperliquid Strategies both had 3 articles in the media. Hyperliquid Strategies' average media sentiment score of 0.28 beat Sagimet Biosciences' score of 0.17 indicating that Hyperliquid Strategies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sagimet Biosciences (SGMT) Competitors

$7.99 +0.84 (+11.75%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$8.11 +0.12 (+1.50%)

As of 08:43 AM Eastern

Compare

SGMT vs. PHAT, PHAR, JANX, AMPH, and PURR

Should you buy Sagimet Biosciences stock or one of its competitors? MarketBeat compares Sagimet Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sagimet Biosciences include Phathom Pharmaceuticals (PHAT), Pharming Group (PHAR), Janux Therapeutics (JANX), Amphastar Pharmaceuticals (AMPH), and Hyperliquid Strategies (PURR).

How does Sagimet Biosciences compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Sagimet Biosciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Phathom Pharmaceuticals' return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Phathom Pharmaceuticals currently has a consensus target price of $23.43, indicating a potential upside of 177.26%. Sagimet Biosciences has a consensus target price of $25.57, indicating a potential upside of 220.04%. Given Sagimet Biosciences' higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Phathom Pharmaceuticals had 17 more articles in the media than Sagimet Biosciences. MarketBeat recorded 20 mentions for Phathom Pharmaceuticals and 3 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.17 beat Phathom Pharmaceuticals' score of 0.01 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sagimet Biosciences has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	3.90	-$221.25M	-$1.28	N/A
Sagimet Biosciences	$2M	130.16	-$51.04M	-$1.34	N/A

Phathom Pharmaceuticals has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.37, meaning that its stock price is 237% more volatile than the broader market.

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Sagimet Biosciences beats Phathom Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Sagimet Biosciences compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

In the previous week, Pharming Group had 22 more articles in the media than Sagimet Biosciences. MarketBeat recorded 25 mentions for Pharming Group and 3 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.17 beat Pharming Group's score of -0.11 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	2 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharming Group has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.37, indicating that its share price is 237% more volatile than the broader market.

Pharming Group has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	1.93	$2.85M	$0.12	85.50
Sagimet Biosciences	$2M	130.16	-$51.04M	-$1.34	N/A

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 11.5% of Sagimet Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pharming Group currently has a consensus target price of $38.67, suggesting a potential upside of 276.87%. Sagimet Biosciences has a consensus target price of $25.57, suggesting a potential upside of 220.04%. Given Pharming Group's higher probable upside, analysts clearly believe Pharming Group is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Pharming Group has a net margin of 2.51% compared to Sagimet Biosciences' net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Summary

Pharming Group beats Sagimet Biosciences on 9 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to Janux Therapeutics?

Sagimet Biosciences (NASDAQ:SGMT) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

In the previous week, Sagimet Biosciences had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 3 mentions for Sagimet Biosciences and 2 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.44 beat Sagimet Biosciences' score of 0.17 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sagimet Biosciences currently has a consensus target price of $25.57, indicating a potential upside of 220.04%. Janux Therapeutics has a consensus target price of $38.08, indicating a potential upside of 138.62%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Sagimet Biosciences is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sagimet Biosciences has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	130.16	-$51.04M	-$1.34	N/A
Janux Therapeutics	$10M	97.32	-$113.62M	-$1.84	N/A

Janux Therapeutics' return on equity of -12.93% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Janux Therapeutics	N/A	-12.93%	-12.23%

Sagimet Biosciences has a beta of 3.37, suggesting that its share price is 237% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market.

Summary

Sagimet Biosciences beats Janux Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Sagimet Biosciences compare to Amphastar Pharmaceuticals?

Sagimet Biosciences (NASDAQ:SGMT) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Sagimet Biosciences currently has a consensus price target of $25.57, indicating a potential upside of 220.04%. Amphastar Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 10.55%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Sagimet Biosciences is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Sagimet Biosciences has a beta of 3.37, meaning that its stock price is 237% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Amphastar Pharmaceuticals has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	130.16	-$51.04M	-$1.34	N/A
Amphastar Pharmaceuticals	$719.89M	1.22	$98.09M	$1.66	11.99

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Sagimet Biosciences' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Sagimet Biosciences. MarketBeat recorded 4 mentions for Amphastar Pharmaceuticals and 3 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.17 beat Amphastar Pharmaceuticals' score of 0.12 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Amphastar Pharmaceuticals beats Sagimet Biosciences on 9 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and Sagimet Biosciences (NASDAQ:SGMT) are related small-cap companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Hyperliquid Strategies currently has a consensus target price of $12.72, indicating a potential upside of 86.74%. Sagimet Biosciences has a consensus target price of $25.57, indicating a potential upside of 220.04%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Hyperliquid Strategies and Hyperliquid Strategies both had 3 articles in the media. Hyperliquid Strategies' average media sentiment score of 0.28 beat Sagimet Biosciences' score of 0.17 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sagimet Biosciences' return on equity of -37.57% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Hyperliquid Strategies has higher earnings, but lower revenue than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	983.70	-$16.01M	-$7.37	N/A
Sagimet Biosciences	$2M	130.16	-$51.04M	-$1.34	N/A

Hyperliquid Strategies has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.37, meaning that its stock price is 237% more volatile than the broader market.

Summary

Sagimet Biosciences beats Hyperliquid Strategies on 10 of the 14 factors compared between the two stocks.

Get Sagimet Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMT vs. The Competition

Export

Metric	Sagimet Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$232.98M	$3.52B	$6.83B	$12.77B
Dividend Yield	N/A	3.77%	2.60%	10.01%
P/E Ratio	-5.96	7.32	279.15	25.53
Price / Sales	130.16	1,279.23	591.00	92.31
Price / Cash	N/A	103.44	72.11	49.39
Price / Book	2.34	17.25	13.02	6.11
Net Income	-$51.04M	-$12.52M	$3.48B	$347.58M
7 Day Performance	13.49%	3.63%	3.39%	4.91%
1 Month Performance	4.99%	-5.38%	-2.80%	-2.06%
1 Year Performance	-10.83%	49.44%	73.07%	21.03%

Sagimet Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMT Sagimet Biosciences	2.3647 of 5 stars	$7.99 +11.7%	$25.57 +220.0%	-5.4%	$232.98M	$2M	N/A	8	News Coverage Upcoming Earnings
PHAT Phathom Pharmaceuticals	2.9433 of 5 stars	$11.65 -2.5%	$24.50 +110.3%	-2.2%	$930.75M	$204.89M	N/A	110	Gap Down
PHAR Pharming Group	3.5083 of 5 stars	$12.75 -2.0%	$38.33 +200.8%	-16.2%	$902.09M	$376.13M	79.66	280	Earnings Report Analyst Forecast Analyst Revision Gap Up
JANX Janux Therapeutics	3.4729 of 5 stars	$14.76 -5.2%	$38.08 +158.0%	-33.2%	$901.96M	$10M	N/A	30	Positive News Upcoming Earnings
AMPH Amphastar Pharmaceuticals	2.537 of 5 stars	$19.96 +4.0%	$22.00 +10.2%	-7.0%	$880.74M	$719.89M	12.03	1,976	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMT) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sagimet Biosciences (SGMT) Competitors

SGMT vs. PHAT, PHAR, JANX, AMPH, and PURR

How does Sagimet Biosciences compare to Phathom Pharmaceuticals?

Summary

How does Sagimet Biosciences compare to Pharming Group?

Summary

How does Sagimet Biosciences compare to Janux Therapeutics?

Summary

How does Sagimet Biosciences compare to Amphastar Pharmaceuticals?

Summary

How does Sagimet Biosciences compare to Hyperliquid Strategies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sagimet Biosciences (SGMT) Competitors

SGMT vs. PHAT, PHAR, JANX, AMPH, and PURR

How does Sagimet Biosciences compare to Phathom Pharmaceuticals?

Is PHAT or SGMT more profitable?

Do analysts prefer PHAT or SGMT?

Does the media refer more to PHAT or SGMT?

Which has stronger earnings & valuation, PHAT or SGMT?

Which has more volatility & risk, PHAT or SGMT?

Do insiders & institutionals believe in PHAT or SGMT?

Summary

How does Sagimet Biosciences compare to Pharming Group?

Does the media refer more to PHAR or SGMT?

Which has more volatility & risk, PHAR or SGMT?

Which has preferable earnings & valuation, PHAR or SGMT?

Do insiders & institutionals have more ownership in PHAR or SGMT?

Do analysts rate PHAR or SGMT?

Is PHAR or SGMT more profitable?

Summary

How does Sagimet Biosciences compare to Janux Therapeutics?

Does the media favor SGMT or JANX?

Do analysts rate SGMT or JANX?

Do insiders and institutionals have more ownership in SGMT or JANX?

Which has higher valuation & earnings, SGMT or JANX?

Is SGMT or JANX more profitable?

Which has more risk and volatility, SGMT or JANX?

Summary

How does Sagimet Biosciences compare to Amphastar Pharmaceuticals?

Do analysts prefer SGMT or AMPH?

Which has more risk and volatility, SGMT or AMPH?

Which has higher earnings & valuation, SGMT or AMPH?

Is SGMT or AMPH more profitable?

Does the media favor SGMT or AMPH?

Do insiders & institutionals believe in SGMT or AMPH?

Summary

How does Sagimet Biosciences compare to Hyperliquid Strategies?

Do insiders & institutionals have more ownership in PURR or SGMT?

Do analysts recommend PURR or SGMT?

Does the media refer more to PURR or SGMT?

Is PURR or SGMT more profitable?

Which has better earnings & valuation, PURR or SGMT?

Which has more risk and volatility, PURR or SGMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools